In recent decades, the emphasis of biomarker research has centered around blood-based markers.
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Non-Hodgkin Lymphoma: Likelihood of Approval
Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug